Neurona nabs $102M to launch pivotal trial of epilepsy cell therapy

Title

Neurona Secures $102 Million to Advance Pioneering Cell Therapy for Drug-Resistant Epilepsy into Phase 3 Trials

Keywords

Neurona Therapeutics, NRTX-1001, epilepsy therapy, cell therapy, Phase 3 EPIC trial, drug-resistant epilepsy, regenerative medicine, GABAergic interneurons, RMAT designation, mesial temporal lobe epilepsy (MTLE).

Key Facts

- Funding and Focus:
Neurona Therapeutics raised $102 million to fund the Phase 3 EPIC trial for its lead cell therapy candidate, NRTX-1001, targeting drug-resistant mesial temporal lobe epilepsy (MTLE) 1 5 6.

- Lead Candidate:
NRTX-1001 is an allogeneic regenerative cell therapy derived from human pluripotent stem cells, designed to deliver GABAergic interneurons that secrete the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). This helps suppress seizure activity by stabilizing hyper-excitable neural networks 2 6 9.

- Trial Design:
The Phase 3 EPIC trial will be a randomized, double-blind, sham-controlled study enrolling adults with drug-resistant MTLE. Outcomes from this pivotal trial will support regulatory submission for potential approval 2 6 9.

- Early Success:
Data from ongoing Phase 1/2 studies showed a 92% median reduction in disabling seizures in a low-dose cohort and a 78% reduction in a high-dose cohort. These results, along with the absence of significant adverse events, highlight the therapy’s potential 1 5 6.

- RMAT Designation:
The U.S. FDA granted NRTX-1001 a Regenerative Medicine Advanced Therapy (RMAT) designation in June 2024, facilitating collaboration with the agency for expedited development 2 6 10.

- Market Impact:
NRTX-1001 offers a non-destructive alternative to traditional brain surgery, which carries risks such as memory and cognitive impairments. It aims to address an unmet need for drug-resistant epilepsy, affecting nearly one-third of epilepsy patients worldwide 2 9 10.

- Future Directions:
Beyond MTLE, Neurona plans to explore NRTX-1001 for other neurological conditions, including neocortical focal epilepsy and Alzheimer’s disease 1 5 9.

- Broader Context:
Despite challenging financial conditions in the biotech sector, Neurona has maintained investor confidence with significant backing from groups like Fidelity, Alexandria Venture Investments, and The Column Group 1 5.